Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Performance of GFR Slope as a Surrogate Endpoint for Kidney Disease Progression in Clinical Trials: A Statistical Simulation.

Greene T, Ying J, Vonesh EF, Tighiouart H, Levey AS, Coresh J, Herrick JS, Imai E, Jafar TH, Maes BD, Perrone RD, Del Vecchio L, Wetzels JFM, Heerspink HJL, Inker LA.

J Am Soc Nephrol. 2019 Jul 10. pii: ASN.2019010009. doi: 10.1681/ASN.2019010009. [Epub ahead of print]

PMID:
31292198
2.

Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadoterate meglumine administration: the NSsaFe study.

McWilliams RG, Frabizzio JV, De Backer AI, Grinberg A, Maes BD, Zobel BB, Gottschalk A.

J Magn Reson Imaging. 2019 Jul 9. doi: 10.1002/jmri.26851. [Epub ahead of print]

PMID:
31287213
3.

Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.

Fellström BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, Sørensen SS, Tesar V, Del Vecchio L; NEFIGAN Trial Investigators.

Lancet. 2017 May 27;389(10084):2117-2127. doi: 10.1016/S0140-6736(17)30550-0. Epub 2017 Mar 28.

PMID:
28363480
4.

Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis.

Inker LA, Mondal H, Greene T, Masaschi T, Locatelli F, Schena FP, Katafuchi R, Appel GB, Maes BD, Li PK, Praga M, Del Vecchio L, Andrulli S, Manno C, Gutierrez E, Mercer A, Carroll KJ, Schmid CH, Levey AS.

Am J Kidney Dis. 2016 Sep;68(3):392-401. doi: 10.1053/j.ajkd.2016.02.042. Epub 2016 Mar 29.

PMID:
27032886
5.

Comparison of peritoneal dialysis and haemodialysis after renal transplant failure.

de Jonge H, Bammens B, Lemahieu W, Maes BD, Vanrenterghem Y.

Nephrol Dial Transplant. 2006 Jun;21(6):1669-74. Epub 2006 Feb 9.

PMID:
16469763
6.

Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus.

Lemahieu WP, Hermann M, Asberg A, Verbeke K, Holdaas H, Vanrenterghem Y, Maes BD.

Am J Transplant. 2005 Sep;5(9):2236-43.

7.
8.
9.

Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: consequences for FK506 assimilation.

Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y.

Kidney Int. 2005 Mar;67(3):1152-60.

10.

Crohn's-like changes in the colon due to mycophenolate?

Dalle IJ, Maes BD, Geboes KP, Lemahieu W, Geboes K.

Colorectal Dis. 2005 Jan;7(1):27-34.

PMID:
15606581
11.

CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus.

Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y.

Am J Transplant. 2004 Sep;4(9):1514-22.

12.

Alterations of CYP3A4 and P-glycoprotein activity in vivo with time in renal graft recipients.

Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem YF.

Kidney Int. 2004 Jul;66(1):433-40.

13.

Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study.

Maes BD, Oyen R, Claes K, Evenepoel P, Kuypers D, Vanwalleghem J, Van Damme B, Vanrenterghem YF.

Kidney Int. 2004 May;65(5):1842-9.

14.

Cyclosporine: advantages versus disadvantages vis-à-vis tacrolimus.

Maes BD, Vanrenterghem YF.

Transplant Proc. 2004 Mar;36(2 Suppl):40S-49S. Review.

PMID:
15041305
15.

The value of tuberculin skin testing in haemodialysis patients.

Wauters A, Peetermans WE, Van den Brande P, De Moor B, Evenepoel P, Keuleers H, Kuypers D, Stas K, Vanwalleghem J, Vanrenterghem Y, Maes BD.

Nephrol Dial Transplant. 2004 Feb;19(2):433-8.

PMID:
14736970
16.

Cessation of steroids in stable renal transplant patients: the Leuven experience.

Maes BD, Claes K, Coosemans W, Evenpoel P, Kuypers D, Pirenne J, Vanrenterghem Y.

Clin Transpl. 2002:181-9.

PMID:
12971448
17.

Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [14C]erythromycin breath and urine test.

Lemahieu WP, Maes BD, Ghoos Y, Rutgeerts P, Verbeke K, Vanrenterghem Y.

Am J Physiol Gastrointest Liver Physiol. 2003 Sep;285(3):G470-82.

18.

Influence of SDZ RAD vs. MMF on gastric emptying in renal transplant recipients.

Maes BD, Evenepoel P, Kuypers D, Geypens B, Ghoos Y, Vanrenterghem Y.

Clin Transplant. 2003 Jun;17(3):171-6.

PMID:
12780664
19.

Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea.

Maes BD, Dalle I, Geboes K, Oellerich M, Armstrong VW, Evenepoel P, Geypens B, Kuypers D, Shipkova M, Geboes K, Vanrenterghem YF.

Transplantation. 2003 Mar 15;75(5):665-72.

PMID:
12640307
20.

Gastric emptying in renal failure patients using the 13C-octanoic acid breath test: facts and artifacts.

Maes BD, Evenepoel P, Geypens B, Rutgeerts P, Ghoos Y.

Perit Dial Int. 2002 Nov-Dec;22(6):732-3; author reply 734-5. No abstract available.

PMID:
12556082
21.

Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients.

Maes BD, Lemahieu W, Kuypers D, Evenepoel P, Coosemans W, Pirenne J, Vanrenterghem YF.

Am J Transplant. 2002 Nov;2(10):989-92.

22.

Role of immunosuppressive drugs in the development of tissue-invasive cytomegalovirus infection in renal transplant recipients.

Kuypers DR, Evenepoel P, Maes BD, Coosemans W, Pirenne J, Vanrenterghem YF.

Transplant Proc. 2002 Jun;34(4):1164-70. No abstract available.

PMID:
12072305
23.

Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors.

Maes BD, Kuypers D, Messiaen T, Evenepoel P, Mathieu C, Coosemans W, Pirenne J, Vanrenterghem YF.

Transplantation. 2001 Nov 27;72(10):1655-61.

PMID:
11726827
24.

The effect of mycophenolate mofetil on hepatitis B viral load in stable renal transplant recipients with chronic hepatitis B.

Maes BD, van Pelt JF, Peeters JC, Nevens F, Evenepoel P, Kuypers D, Messiaen T, Fevery J, Vanrenterghem YF.

Transplantation. 2001 Sep 27;72(6):1165-6. No abstract available.

PMID:
11579320
25.

Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine.

Maes BD, Vanwalleghem J, Kuypers D, Ghoos Y, Rutgeerts PJ, Vanrenterghem YF.

Transplantation. 1999 Nov 27;68(10):1482-5.

PMID:
10589943
26.

Anti-interleukin-2 receptor monoclonal antibodies in renal transplantation.

Maes BD, Vanrenterghem YF.

Nephrol Dial Transplant. 1999 Dec;14(12):2824-6. No abstract available.

PMID:
10570080
27.

Gastric emptying in hyperemesis gravidarum and non-dyspeptic pregnancy.

Maes BD, Spitz B, Ghoos YF, Hiele MI, Evenepoel P, Rutgeerts PJ.

Aliment Pharmacol Ther. 1999 Feb;13(2):237-43.

28.

Gastric emptying flow curves separated from carbon-labeled octanoic acid breath test results.

Maes BD, Mys G, Geypens BJ, Evenepoel P, Ghoos YF, Rutgeerts PJ.

Am J Physiol. 1998 Jul;275(1):G169-75. doi: 10.1152/ajpgi.1998.275.1.G169.

PMID:
9655697
29.

Gastric emptying of the liquid, solid and oil phase of a meal in normal volunteers and patients with Billroth II gastrojejunostomy.

Maes BD, Hiele MI, Geypens BJ, Ghoos YF, Rutgeerts PJ.

Eur J Clin Invest. 1998 Mar;28(3):197-204.

PMID:
9568465
30.

13C-Octanoic acid breath test for gastric emptying rate of solids.

Maes BD, Geypens BJ, Ghoos YF, Hiele MI, Rutgeerts PJ.

Gastroenterology. 1998 Apr;114(4):856-9. No abstract available.

PMID:
9547107
31.

Gastric emptying rate of solids in patients with nonulcer dyspepsia.

Maes BD, Ghoos YF, Hiele MI, Rutgeerts PJ.

Dig Dis Sci. 1997 Jun;42(6):1158-62.

PMID:
9201077
32.

Gastric emptying and Helicobacter pylori infection in duodenal ulcer disease.

Perri F, Ghoos YF, Maes BD, Geypens BJ, Ectors N, Geboes K, Hiele MI, Rutgeerts PJ.

Dig Dis Sci. 1996 Mar;41(3):462-8.

PMID:
8617116
33.

Relation between gastric emptying rate and rate of intraluminal lipolysis.

Maes BD, Ghoos YF, Geypens BJ, Hiele MI, Rutgeerts PJ.

Gut. 1996 Jan;38(1):23-7.

34.

Relation between gastric emptying rate and energy intake in children compared with adults.

Maes BD, Ghoos YF, Geypens BJ, Hiele MI, Rutgeerts PJ.

Gut. 1995 Feb;36(2):183-8.

35.

Influence of octreotide on the gastric emptying of solids and liquids in normal healthy subjects.

Maes BD, Ghoos YF, Geypens BJ, Hiele MI, Rutgeerts PJ.

Aliment Pharmacol Ther. 1995 Feb;9(1):11-8.

PMID:
7766738
36.

[*C]octanoic acid breath test to measure gastric emptying rate of solids.

Maes BD, Ghoos YF, Rutgeerts PJ, Hiele MI, Geypens B, Vantrappen G.

Dig Dis Sci. 1994 Dec;39(12 Suppl):104S-106S.

PMID:
7995200
37.

Combined carbon-13-glycine/carbon-14-octanoic acid breath test to monitor gastric emptying rates of liquids and solids.

Maes BD, Ghoos YF, Geypens BJ, Mys G, Hiele MI, Rutgeerts PJ, Vantrappen G.

J Nucl Med. 1994 May;35(5):824-31.

38.

Pharmacological modulation of gastric emptying rate of solids as measured by the carbon labelled octanoic acid breath test: influence of erythromycin and propantheline.

Maes BD, Hiele MI, Geypens BJ, Rutgeerts PJ, Ghoos YF, Vantrappen G.

Gut. 1994 Mar;35(3):333-7. Erratum in: Gut 1994 Jun;35(6):866.

39.

Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test.

Ghoos YF, Maes BD, Geypens BJ, Mys G, Hiele MI, Rutgeerts PJ, Vantrappen G.

Gastroenterology. 1993 Jun;104(6):1640-7.

PMID:
8500721

Supplemental Content

Support Center